| INTRODUC TI ON
Hepatitis B virus (HBV) reactivation occurring in patients undergoing cytotoxic chemotherapy and/or immunosuppressive therapy is a well-recognized complication of considerable clinical importance.
Reactivation of HBV is more often seen in hepatitis B carriers who are positive for hepatitis B surface (HBs) antigen (Ag) and for antibody (Ab) against hepatitis B core (HBc). Acute hepatitis, that is, de novo hepatitis, is likely to occur because of HBV reactivation during chemotherapy and/or immunosuppressive therapy given to patients with transplanted organs and leads to variable manifestations that range from subclinical serum aminotransferase elevation to fatal fulminant hepatitis.
However, a few cases of HBV reactivation in patients with resolved infection as defined by negative HBsAg and positive HBcAb with or without HBsAb have been reported during chemotherapy or immunosuppressive therapy.
1,2 The incidence of de novo hepatitis due to HBV reactivation in HBsAg-negative patients with malignant lymphoma treated with corticosteroid-containing cytotoxic chemotherapy was reported to be 2.7% over a 4-year period and 3.3% during a 12.4-month follow-up. 3, 4 However, use of rituximab, an anti-CD20-directed monoclonal antibody, in combination with corticosteroid-containing chemotherapy, has been frequently associated with HBV reactivation and resultant de novo hepatitis. [4] [5] [6] Most of these reports come from the fields of oncology and transplantation, with a growing number of cases being reported in patients with rheumatic disease who are also undergoing immunosuppressive therapy. The incidence of HBV reactivation was reported to be 7/135 (5.2%) after a 1-year prospective observation in rheumatoid arthritis patients with resolved hepatitis B treated with corticosteroids, immunosuppressants and/or disease-modifying antirheumatic drugs (DMARDs). 7 A recent prospective observational study in Japan has reported that HBV reactivation among rheumatic disease patients with resolved HBV infections treated with prednisone, immunosuppressants and/or biological DMARDs, occurred in 35/1042 (3.4%) of individuals over a period of 2 years. 8 Estimated incidence rates of HBS reactivation and hence de novo hepatitis vary, likely due to differences among the patient populations studied, drugs administered and the duration of follow-up.
Of all the traditional immunosuppressive medications, corticosteroids have been most often implicated in the induction of HBV reactivation. The risk of HBV reactivation in patients with inflammatory bowel disease, vasculitis, sarcoidosis and autoimmune disease might differ, depending on whether the patients are HBsAg-positive/ HBcAb-positive or HBsAg-negative/HBcAb-positive, whether the dosage of chronic prednisone therapy is low, moderate or high, or whether the duration is short or longer than 4 weeks. 8, 9 However, the exact incidence rate of HBV reactivation in HBsAg-negative/ HBcAb-positive patients with autoimmune disease such as rheumatoid arthritis treated only with corticosteroids has not been fully evaluated.
On the other hand, adrenal insufficiency is usually treated with optimal replacement dose corticosteroids, equivalent to 5 mg of prednisone/day, to achieve physiological plasma cortisol levels comparable to those in healthy individuals. The incidence of HBV reactivation in patients with adrenal insufficiency given a physiological dose of corticosteroids is also unknown. Therefore, we investigated the incidence of the reactivation of HBV in HBsAg-negative patients in adrenal insufficiency patients with corticosteroid therapy. And we also evaluated the incidence rate of HBV reactivation in patients with rheumatic disease treated with corticosteroids with or without immunosuppressants and/or DMARDs as the positive control. The levels of HBsAg, HBsAb and HBcAb were determined in all the patients at the beginning of the study. An HBsAg level of <0.04 IU/mL was considered to be negative. Anti-HBs levels of ≥10 IU/L were defined as positive, as were HBcAb levels ≥1.0 s/co.
| PATIENTS AND ME THODS
Real-time PCR was performed on HBV-DNA in patients who were positive for HBsAb and/or HBcAb, and the resulting HBV-DNA level was considered to be positive if the level was ≥2.1 log copies/mL. Patients who were converted to HBV-DNA-positive status were defined as those who were HBsAg-negative at the start of the treatment but became HBV-DNA-positive during treatment. We determined the incidence rates of conversion to HBV-DNA-positive status in patients with adrenal insufficiency or rheumatic disease.
The levels of aspartate transaminase (AST), alanine transaminase (ALT), lactate dehydrogenase (LDH) and γ-GTP were also measured during the observation period to assess liver function.
| Statistical analysis
All the data are shown as mean ± SE. The chi-squared test and ANOVA followed by a Tukey-Kramer test were performed for comparisons, using JMP 9 statistical software. A P-value of less than 0.05 was considered to be statistically significant.
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| RE SULTS
A total of 66 patients (32 men and 34 women) had begun, or were receiving, corticosteroid replacement therapy for adrenal insufficiency. The diagnosis of diseases that result in adrenal insufficiency is shown in Table 1 . The most common diagnosis was generalized hypopituitarism (n = 44), followed by isolated ACTH deficiency (n = 8), primary or postoperative adrenal insufficiency (n = 8), and so on. On the other hand, 220 patients (48 men and 172 women) were on corticosteroid treatment with or without immunosuppressants and/or DMARDs for various rheumatic diseases. Rheumatoid arthritis was the most common disease, with 80patients, followed by systemic lupus erythematosus (n = 46), overlap syndrome (n = 19) and polymyalgia rheumatica (n = 13), and so on. Table 2 shows the patients' characteristics. Individuals with rheumatic disease were older than those with adrenal insufficiency.
The duration of corticosteroid therapy did not differ among the three groups. The daily maintenance dose of corticosteroids was significantly different among the three groups (P < 0.0001). The doses of corticosteroids (prednisone or equivalent), that is 6.6 ± 0.5 mg and 6.5 ± 0.5 mg in patients with rheumatic disease treated with corticosteroids alone, and corticosteroids plus other immunosuppressants and DMARDs, respectively, were significantly larger than those (4.2 ± 0.2 mg) in patients with adrenal insufficiency (P < 0.05).
TA B L E 2 Characteristics of the study population
Maximum daily doses of corticosteroids differed significantly among the three groups (P < 0.0047). The dose of corticosteroids in patients with rheumatic disease treated with only corticosteroids or corticosteroids plus other immunosuppressants and/or DMARDs, that is 24.1 ± 1.8 and 18.9 ± 1.8 mg, respectively, were significantly greater than 4.2 ± 0.2 mg in patients with adrenal insufficiency (P < 0.05).
The levels of AST, ALT, LDH and γ-GTP in the three groups are also shown in Table 2 . No statistically significant difference was noted in these liver function tests.
As shown in Table 3 As shown in Table 4 It should be noted that, among the patients who had converted to HBV-DNA-positive status, corticosteroids were administered as monotherapy in three patients and as combination therapy in three patients. Of these patients, one was co-administered with melpharan, while two were co-administered with methotrexate and either tacrolimus or abatacept (Table 4 ).
| D ISCUSS I ON
In this study, we investigated the incidence of HBV reactivation among HBsAg-negative patients treated with a physiological dose of corticosteroids as replacement therapy and a pharmacological dose for anti-inflammatory and/or immunosuppressive purposes. First of all, patients who showed negative for both HBsAb and HBcAb at the beginning of and/or during the study corresponded to about 85% of the patients included in the study. They were believed to have not been exposed to HBV, although we cannot completely rule out the possibility that several patients had been exposed to HBV but turned out to be seronegative, that is, HBsAg-negative. Those patients who had never been exposed to HBV during the study period provide no value in a study to elucidate the effects of corticosteroids on the reactivation of HBV. Still, it is meaningful to learn about how many patients were exposed to HBV, and how many were not during the study period. In the present study Abbreviations: HBcAb, antibody against hepatitis B core; HBsAb, antibody against hepatitis B surface; HBsAg, hepatitis B surface antigen. patients. This is consistent with the previous study which showed no differences in serum liver enzyme levels between patients with and without recurrent hepatitis B. body. 13 In fact, a corticosteroid dose equivalent to 30 mg/d of prednisone results in the proliferation of HBV and imposes a risk of HBV reactivation associated with high-dose steroids.
TA B L E 3 Results of HBsAb and HBcAb measurements
In contrast, it should be noted that we had no cases of HBV reactivation among adrenal-insufficient patients on corticosteroid replacement therapy. The daily maintenance and maximum doses of corticosteroids were both 4.2 ± 0.2 mg, which were significantly lower than those prescribed to rheumatic disease patients. In recent reviews by Perrillo et al 14 It has been reported that a greater number of HBcAb-positive and HBsAb-negative patients experience HBV reactivation, compared with patients who are HBcAb-negative and anti-HBs-positive. 6, 17 In our study, all six HBV-positive patients were positive for HBcAb, suggesting that HBcAb has considerable potential as a marker and screening tool for patients with resolved HBV infection.
Our results suggest that special attention should be given to the possible reactivation of HBV in patients who are positive for HBcAb.
In our study, patients who experienced HBV reactivation were aged between 46 and 68 years, with five of the six patients aged over 60. Other studies have reported age to be significantly associated with HBV reactivation in HBsAg-negative patients with B-cell lymphoma or rheumatic disease treated with rituximab plus corticosteroid-containing chemotherapy or corticosteroids, immunosuppressive drugs and/ or DMARDs. 8, 10 However, some rheumatic disease patients in their 20s and 30s treated with immunosuppressive and biological drugs were reported to show HBV reactivation. 18 Moreover, in one Japanese study that evaluated 135 resolved hepatitis B patients with rheumatoid arthritis, age was not a predictive factor for HBV reactivation. 7 Therefore, attention should be paid to not only the elderly but also to younger individuals with respect to HBV reactivation, especially when biological DMARDs are being co-administered with corticosteroids. In addition, although the male gender has been reported to be more associated with HBV reactivation in patients with chemotherapy-treated lymphoma, 3, 5 five of the six patients in our present study were female. This is consistent with previous studies in rheumatic disease which report that the male gender was not necessarily associated with HBV reactivation on corticosteroids with or without biological agents. This study has several limitations. First, it was designed as a cross-sectional observational study, not a randomly controlled prospective study. Second, the rate of incidence of HBV reactivation did not show a statistically significant difference among the three groups.
Nevertheless, the difference is clear at a glance: HBV reactivation occurred in none of the 66 patients with adrenal insufficiency who were treated with a physiological dose of corticosteroids, but did occur in three out of 101 patients with rheumatic disease given a pharmacological dose of corticosteroids only, and in three out of 119 patients with rheumatic disease given a pharmacological dose of corticosteroids, together with immunosuppressive drugs and/or DMARDs. This might be due to the small number of patients observed and the relatively short observation period of only 13 months. To guarantee the safety of replacement therapy with a physiological dose of corticosteroids in patients with adrenal insufficiency, and to dispel their concerns for HBV reactivation, further prospective studies will be needed, with a longer observational period and with a larger population of patients with adrenal insufficiency. This should also apply to patients with rheumatic disease, to further ascertain the influence of treatment comprising corticosteroids and immunosuppressants with or without DMARDs.
In conclusion, our present study suggests that, although corticosteroid replacement therapy for adrenal insufficiency might be safe with respect to HBV reactivation, we should remain alert to the risk of HBV reactivation during corticosteroid therapy in patients with rheumatic disease, since the dose of corticosteroid administered is usually high, especially at the beginning, and since other immunosuppressive and molecular-targeted drugs are co-administered.
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